Pfizer South Africa
Our Purpose
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
We strive to set the standard for quality, safety and value in the discovery, development and manufacture of healthcare products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer healthcare products.
Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.
We believe that to be truly healthy, it takes more than medication. This is why Pfizer South Africa is a healthcare company that’s dedicated to helping South Africans live healthier lives.
“When you have your health, you cando whatever is a priority to you.
When you don’t, you can’t.
What I love about being part ofPfizer is that it’s always on our mind.”
Jennifer PowerCOUNTRY MANAGER
3
These business units are underpinned by Enabling Functions that advance all of the company’s businesses, organisations and priorities (such as Legal, Regulatory, HR, Business Technology, Finance and Public Affairs).
Pfizer Innovative Health (PIH) is committed to discovering, developing, manufacturing and delivering innovative products and vaccines that change the outcome of chronic conditions and devastating diseases.
The PIH portfolio includes existing treatments and the development of new treatments in the following therapy areas:
• Inflammation & Immunology
• Metabolic Disease & Cardiovascular Risk
• Neuroscience & Pain
• Oncology
• Rare Diseases
• Vaccines
Pfizer Essential Health (PEH) combines the history of industry leadership,
comprehensive knowledge of global healthcare markets, and a vast portfolio of trusted,
quality medicines to benefit patients around the world at virtually every stage of life.
The PEH portfolio includes medicines that treat patients for a variety of acute and
chronic conditions across many therapeutic areas, including many critical medicines and
sterile injectables:
• Anti-Infectives & Sedation
• Women’s and Men’s Health
• Cardiovascular Disease
• Neuroscience
• Pain
Pfizer Consumer Health (PCH) develops, manufactures and markets leading non-
prescription medicines, low risk medical devices (for external use) and health products
(mainly supplements).
Our Business
Our commercialbusiness is dividedinto three Business
Units, each of which broadly work in
different areas of medicine.
These Business Units are:
Pfizer Innovative Health (PIH),
Pfizer Essential Health (PEH),
and
Pfizer Consumer Health (PCH).
We have a culture of ownership and excellence, and empower our colleagues to achieve beyond their expectations within an open and inclusive environment. We focus intensely on colleague development and a joint commitment to excellence. We are working to drive transformation and contribute to socio-economic advancement via a holistic empowerment strategy aligned to the B-BBEE Act and Codes of Good Practice.
Our Culture and Values
We own and live our values to deliver on
customer expectations, and together make Pfizer
a wonderful place at which to work.
Integrity
Innovation
Respect for People
Customer Focus
Collaboration
Leadership
Performance
Community
Quality
“I would like people to think about Pfizer not as a building or a logo or a corporation, but rather as a collective of individuals who
are passionate about what they come to work to do every single day –
which is to help bring therapies to people that significantly improve their lives.”
Jennifer PowerCOUNTRY MANAGER
the business. in the marketplace.
Let’s discuss behaviors. results. in one another.
O W N I T
OWN WIN NO JERKS IMPACT TRUST
Seize opportunities to think differently,
take risks, try something new.
Advocate and drive long-term,
aligned strategies that advance our
mission and shape the industry.
Confront corrosive, self-serving and mean-spirited
behaviors: it’s everyone’s responsibility.
Deliver on commitments with speed, decisiveness,
and integrity.
Invest in candid and constructive debate to ensure
each other’s success:
it’s time forstraight talk.
Pfizer Worldwide
5
Cardiovascular
Inflammation
Gastroenterology Haematology
Biosimilars
MetabolicDisease
Oncology
InfectiousDiseases
Oncology &Inflammation
Vaccines
Pfizer Worldwide
175 Markets
64 Manufacturing Sites
134 Logistics Centres
200+ Supply Partners
24 500+ SKUs
40+Technologies / Platforms
150years
300+ Employees
850+ Major Product Groups
Therapeutic / Disease Areas Being Studied 9
200+ New R&D Collaborations
20+ Clinical Trials75
Trial Centres
One of SA’s Top 5 American Employers
9 700+ Employees
100 Different Prescription Products
Share Product and Disease Knowledge with 4000+ Healthcare Professionals
Pfizer Southern Africa
Opens in Brooklyn, New York as a fine chemical business
World’s largest producer of penicillin
Production of citric acid puts Pfizer on
the map
Becomes a publically traded company
1849 19441880s 1942History and Milestones of Pfizer South Africa
Leadership Team
“The most amazing part of my job
is being part of a team that finds
a solution to a problem without
an obvious answer.
It’s to innovate, to be part of improving
healthcare for individuals, and this team here at Pfizer
does that every singleday.”
Jennifer PowerCOUNTRY MANAGER
Jennifer PowerCOUNTRY MANAGER
Doreen NelHUMAN RESOURCES
DIRECTOR
Matthew MoodleyLEGAL DIRECTOR
William ThemaneBUSINESS ANALYTICS
& INSIGHTS LEAD
Larne PearsonPRODUCT QUALITY
LEAD
Mahnqwa KhumaloFINANCE DIRECTOR
Dr. Tobeka BoltinaMEDICAL DIRECTOR
Rhulani NhlanikiPFIZER INNOVATIVE
HEALTH CLUSTER LEAD
Bridget BarnardLOGISTICS & SUPPLY
CHAIN MANAGER
Paul BrandSALES DIRECTOR
Marianne ZennonCOUNTRY
REGULATORY HEAD
Elaine CrossBUSINESS
OPERATIONS LEAD
Carl SmithBUSINESS
TECHNOLOGY LEAD
Karen HulettMARKETING DIRECTOR
Atetia VisagieGLOBAL COMMERCIAL OPERATIONS CLUSTER
LEAD
Johnny MolotoDIRECTOR PUBLIC
AFFAIRS POLICY ACCESS & COMMUNICATIONS
Sue CartwrightPFIZER CONSUMER
HEALTH COMMERCIAL LEAD
7
Enters SA market with distribution via
Petersen Ltd.
Branches into agricultural sector
Acquires Choats Co. and African Chemical
Corporation
Sets up own pharmaceutical
promotional activity in SA
World headquarters established in
New York
Johannesburg becomes regional HQ
for Southern Africa
1951 1950s 19621953 1961 1967
Researchand Development Research and Development is at the heart of fulfilling our purpose to help people live healthier lives. Innovation is also the key to sustaining our growth and profitability. As such, the quest for innovative solutions invigorates the Pfizer community globally, and we have more than 200 new R&D collaborations active worldwide.
We are advancing next-generation science to accelerate the development of breakthrough medicines and vaccines, and translate technologies into therapies that significantly improve patients’ lives.
The process is arduous and expensive: it takes an average of 12 years for a drug to reach the market. We therefore focus our resources in disease areas with the best chance of scientific and commercial success. Clinical studies find the answers necessary to develop innovative new therapies, and clinical trials make it possible for participating patients to receive state-of-the-art care from the leading experts in the field.
In South Africa alone, we run over 20 Clinical Trials at 75 Trial Centres annually.
“We’re contributing to the knowledge economy, we’re contributing to innovation, and we are contributing to the man in the street in making sure that the right vaccine gets to where it needs to get to so that he can focus on other aspects of life.”
Scientific CollaborationsBiovac Technology Transfer The Pfizer-Biovac Technology Transfer is a public-private initiative to locally manufacture a vaccine crucial for the prevention of pneumonia-related deaths, particularly in children up to the age of five. Launched in 2015, the project entails a skills and technology transfer from Pfizer to Biovac that will provide it with the capability to manufacture the vaccine by 2019.
Morena MakhoanaBIOVAC CEO
Pietermaritzburg manufacturing plant
commissioned
Further acquisitions and mergers grow
the company
Celebrates 150th anniversaryForbes Company of the Year
Achieves Top 10 status in the industry
1968 1970s 1999
Our supplier quality management systems help ensure high quality materials are procured for our products.
Our conveyance security standards enable our medicines to be transported safely and help prevent illicit dugs from entering the corporate supply chain.
We enact applicable local market legislation and regulations that strengthen our supply chain.
Our security programmes help protect our warehousing facilities and warehouses from criminals.
Our global packaging technology programme is designed to help prevent counterfeiting of our products.
Our global bar coding programme allows us to add authentication capability to our products.
Our established monitoring systems help us scrutinise the marketplace for the presence of counterfeit and unsafe product.
Supply Chain
Security
History and Milestones of Pfizer South Africa
9
Merges with Warner-LambertTop 5 pharma company in SA
MoU with DoH: establishes anti-fungal partnership programme to help treatment of HIV/AIDS
Acquires Pharmacia Corporation
Partners with Biovac Institute in a Technology Transfer
Initiative
Acquires Wyeth
2000 2002 20152009
An environment in which everyone in Pfizer understands and embraces their responsibility for protecting product quality and patient safety. Quality Culture is and has always been the “key” to enable us to provide safe and quality medicines.
A holistic, multi-faceted approach to ensure product quality and adherence to Good Manufacturing Practice (cGMP).
Organised according to integrated and interconnected quality processes (such as Governance & Internal Organisation, Product Quality Assurance & Operations, Contractor / Supplier Management and Oversight) to ensure high and consistent product quality.
Ensures high commitment to Quality and Regulations from our suppliers, so that consistent compliance for products, processes and facilities is maintained.
Our global adverse event reporting database helps identify potential issues quickly, and helps ensure product quality and safety.
Processes and procedures for timely and accurate safety monitoring of investigational and marketed products.
We strive to provide the framework for quality and Environmental Health & Safety (EHS) challenges / risks through the successful collaboration with our industry, senior leadership and regulators.
Strong Quality Culture:
Management Oversight:
Global Quality Systems:
Supplier Standards / Oversight:
Adverse Event Reporting:
Quality / Safety Monitoring:
Innovation:
Drive Pfizer’s transformation to contribute to the country’s socio-economic advancement
Pfizer understands the B-BBEE policy and regulatory environment in South Africa and seeks to promote and achieve the objectives of B-BBEE by driving transformation from within its South African business. In order to do so, Pfizer believes that it should implement a holistic B-BBEE strategy which–
• is capable of making a significant impact on the beneficiaries of such B-BBEE strategy; and
• takes into account the content of the B-BBEE Act, as well as the applicable B-BBEE codes of good practice.
QualityControl
At Pfizer we have a proud tradition of ensuring that the communities in which we live and work benefit from our investment and from our partnerships with key stakeholders to expand access to treatment and affordable healthcare. Pfizer’s corporate responsibility activities are focused on investing the full range of our resources - people, skills, expertise and funding - to broaden access to medicines and strengthen healthcare delivery for underserved people around the world. Several of Pfizer’s corporate public health partnerships have had a positive impact on healthcare in South Africa and we have both a local and global social responsibility focus.
Our business strategy is aligned to South Africa’s socio-economic transformation priorities and we use the B-BBEE scorecard as the objective measure to track the progress we are making against all the critical elements. In this regard, our contribution to the local economy is a journey rather than an event. Every year, we build on our previous successes as part of our long-term commitment to the country.
Our Value Add
to the South
African Economy
Unjani Clinics Unjani Clinics is an Enterprise Development initiative that empowers black woman Professional Nurses to own and operate their own primary healthcare clinics in their communities, creating permanent jobs and building sustainable businesses. Founded on an owner-operator model, the clinics serve the “bottom of the pyramid” and underserved markets, ensuring an affordable, quality primary healthcare service and the supply of quality medicines to the people of South Africa. The clinics are based in communities, ensuring that the service is delivered at the point of need. Pfizer sponsored a clinic in Hammanskraal and has provided funding for 28 Mindray DP10 Ultrasonic Diagnostic Imaging Systems, printers, trolleys, as well as as certified training for 28 clinics in the network.
11
Antifungal Partnership ProgrammeSince 2000, Pfizer has been in partnership with the Department of Health, donating treatments for two opportunistic fungal infections associated with HIV and AIDS (cryptococcal meningitis and esophageal candidiasis). Sixteen years into the programme, South Africa has 1 264 sites, accounting for almost 50% of all the sites globally. In 2016 alone, the value of the programme was R200 million.
The Nelson Mandela Children’s Hospital (NMCH) NMCH is fast realising the late Nelson Mandela’s dream of a hospital offering the children of Southern Africa state-of-the-art healthcare. Pfizer donated R3 million towards the hospital’s construction and the purchase of two Ultrasound Imaging Units to detect cardiothoracic defects in babies and children.
Public Health Enhancement FundPfizer is a member of the Public Health Enhancement Fund (PHEF), which is a social compact between 23 private healthcare companies and the Ministry of Health. The purpose of the PHEF is to contribute towards the production of medical doctors, researchers in HIV/AIDS and TB as well as capacity building for public hospital administrators. Pfizer participates in this programme by making annual financial contributions based on a percentage of our earnings. There is therefore a direct correlation between what we earn from any transaction and what we give back to society.
“When a global company such as
Pfizer gets involved in a grassroots
initiative such as Unjani, I think
it’s important to South Africa. It’s
not only about empowerment of women and
job creation, but creating access
to much needed healthcare
services and better lives for all.
Isn’t itwonderful that
you can go to work every single
day and know that you are
actually making a difference.”
Lynda ToussaintUNJANI CLINICS CEO
0860 Pfizer (734937)
www.pfizer.co.za
Physical Address85 Bute Lane Sandton 2146
Postal AddressPfizer Laboratories (Pty) Ltd.PO Box 783720 Sandton 2196
Working Togetherfor a Healthier World®
Pfizer South Africa